Exelixis
EXEL
#1612
Rank
ยฃ7.63 B
Marketcap
ยฃ27.28
Share price
0.11%
Change (1 day)
48.57%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): ยฃ0.53 Billion

According to Exelixis's latest financial reports the company's current earnings are ยฃ2.16 Billion. , an increase over its 2023 earnings that were of ยฃ0.19 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 ยฃ0.51 B164.69%
2023 ยฃ0.19 B9.89%
2022 ยฃ0.17 B-20.33%
2021 ยฃ0.22 B124.82%
2020 ยฃ98.63 M-67.14%
2019 ยฃ0.30 B-11.94%
2018 ยฃ0.34 B185.09%
2017 ยฃ0.11 B-325.82%
2016 -ยฃ52.94 Million-58.12%
2015 -ยฃ0.13 Billion-37.61%
2014 -ยฃ0.21 Billion9.75%
2013 -ยฃ0.19 Billion65.96%
2012 -ยฃ0.12 Billion-291.63%
2011 ยฃ58.04 M-195.59%
2010 -ยฃ60.72 Million-42.17%
2009 -ยฃ0.11 Billion-18.98%
2008 -ยฃ0.13 Billion-6.99%
2007 -ยฃ0.14 Billion46.3%
2006 -ยฃ95.25 Million33.25%
2005 -ยฃ71.48 Million-30.92%
2004 -ยฃ0.11 Billion44.29%
2003 -ยฃ71.71 Million12.86%
2002 -ยฃ63.55 Million22.79%
2001 -ยฃ51.75 Million60.14%
2000 -ยฃ32.32 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
ยฃ3.31 B 544.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ5.98 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ15.98 B 3,011.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.32 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.47 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ13.14 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ8.37 B 1,530.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ32.25 Million-106.28%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ21.9 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA